What Is Cerebrolysin? Mechanism and Evidence Explained

TL;DR: Cerebrolysin is a low-molecular-weight peptide and amino acid preparation derived from porcine (pig) brain tissue, containing neurotrophic factors including BDNF, GDNF, NGF, and CNTF alongside additional uncharacterized peptide fragments. Unlike most research peptides documented in this journal, Cerebrolysin is an approved pharmaceutical drug in Austria, Russia, China, and numerous countries across Eastern Europe and Asia, where it is studied and used clinically for acute ischemic stroke, vascular dementia, and Alzheimer’s disease. A substantial body of RCT data and multiple Cochrane meta-analyses exist, but trial results are inconsistent, Cochrane reviews rate evidence quality as very low to moderate, and the compound is not FDA approved. This article documents the published trial evidence honestly, including both positive RCT findings and the critical Cochrane conclusions.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Cerebrolysin is not approved by the FDA for human use in the United States. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. References to Cerebrolysin’s approved-drug status in other jurisdictions are documented regulatory facts, not endorsements of use of any research material. All study findings described below refer to published peer-reviewed research. For adults 21+ with a research interest only.

What Is Cerebrolysin? Definition and Origins

Cerebrolysin is a heterogeneous low-molecular-weight peptide preparation derived from porcine brain tissue through enzymatic degradation. As described in the published literature and the Cochrane reviews, it consists of small peptide fragments (approximately 25% of the preparation by weight) and free amino acids (approximately 75%), the peptide fraction containing known neurotrophic molecules including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF), alongside additional uncharacterized peptide fragments whose individual contributions to the preparation’s biological activity are not fully established.

The preparation is manufactured by EVER Neuro Pharma GmbH (formerly Ebewe Pharma) in Austria, where it is approved as a pharmaceutical drug. It is also approved and in clinical use in Russia, China, and numerous countries in Eastern Europe and Asia. Trade names include Cerebrolysin, FPF-1070, and FPF1070 in earlier literature. It is typically administered as an intravenous infusion in clinical and trial settings.

This approved-drug status in multiple jurisdictions distinguishes Cerebrolysin from many research peptides documented in this journal: it has a formal regulatory history, a substantial base of industry-supported and independent clinical trial data, and an existing literature of Cochrane-reviewed meta-analyses. That regulatory history is documented here as fact; it does not constitute an endorsement of the use of any research material.

What Is Cerebrolysin’s Proposed Mechanism? What the Research Documents

Cerebrolysin does not operate through a single defined receptor target. The published literature characterizes it as exerting neurotrophic and neuroprotective effects through the action of its constituent peptide fragments, particularly those with activity analogous to endogenous neurotrophic factors.

Neurotrophic Factor Activity: BDNF, GDNF, NGF, and CNTF

A 2012 review by Menon et al., published in CNS & Neurological Disorders Drug Targets, characterized Cerebrolysin as “a mixture of different neurotrophic factors” including BDNF, GDNF, NGF, and CNTF alongside additional peptide fragments, and examined its neuroprotective effects in a spinal cord injury animal model, documenting reduction of spinal cord water content, plasma protein leakage, and injured neuron counts at therapeutic doses (PMID 22229324). The neurotrophic factor composition of the preparation is the primary proposed mechanism by which Cerebrolysin exerts its documented biological effects, though the relative contributions of individual constituents remain an active area of study.

The BDNF/GDNF-like activity attributed to Cerebrolysin’s peptide fraction is mechanistically relevant to the neurological indications in which it has been studied: BDNF and GDNF are established survival and differentiation factors for neurons in the central and peripheral nervous systems, with documented roles in neuroplasticity and neuroprotection following ischemic injury. Researchers interested in the comparison between Cerebrolysin’s mechanism and synthetic neuropeptide analogs should also consult the Semax profile, which documents a BDNF-upregulating synthetic peptide with a more characterized receptor interaction.

Blood-Brain Barrier Penetration and Neuroprotection

A consistent finding in the preclinical and mechanistic literature is that Cerebrolysin’s small molecular weight allows its constituent peptides to cross the blood-brain barrier following systemic administration, a property that distinguishes it from larger protein neurotrophic factors, which do not cross the BBB efficiently. The neuroprotective effects documented in clinical trials are proposed to reflect both direct neurotrophic support of surviving neurons and protection of the blood-brain barrier in the setting of acute ischemic injury.

What Does the Clinical Evidence Show? RCTs, Meta-Analyses, and Cochrane Reviews

Cerebrolysin has an unusually large clinical trial base relative to most compounds documented in this journal. The following documents the evidence by condition, presenting both positive findings and the critical assessments from independent Cochrane reviews. Evidence quality ratings are those assigned by the Cochrane reviewers, not by this publication.

Acute Ischemic Stroke: The CARS Trial and Cochrane Review

The most prominent industry-sponsored RCT is the Cerebrolysin and Recovery After Stroke (CARS) trial, published by Muresanu et al. in Stroke in 2016. This prospective, randomized, double-blind, placebo-controlled, multicenter study enrolled subjects who received Cerebrolysin (30 mL/day) or placebo for 21 days beginning 24–72 hours after stroke onset, alongside a standardized rehabilitation program. The study reported a large superiority of Cerebrolysin on the Action Research Arm Test at day 90 (Mann-Whitney estimator 0.71; 95% CI 0.63–0.79; P<0.0001) and a small-to-medium benefit on global status across 12 outcome scales (PMID 26564102). The authors themselves noted the study was exploratory with a relatively small sample size and called for confirmation in a large-scale RCT.

The independent Cochrane Review of Cerebrolysin for acute ischaemic stroke by Ziganshina et al. (2017), covering six RCTs and 1, 501 participants, reached a more cautious conclusion: the findings do not demonstrate clinical benefits of Cerebrolysin for treating acute ischaemic stroke, and there was moderate-quality evidence of an increase in non-fatal serious adverse events in the Cerebrolysin group (RR 2.47; 95% CI 1.09–5.58) compared to placebo (PMID 28430363). The review noted that three of the six included studies were supported by EVER Neuro Pharma, a relevant conflict-of-interest consideration. Total serious adverse event rates were not significantly different between groups.

Two independent meta-analyses (not Cochrane) reached similarly cautious conclusions. Zhang et al. (2017), pooling seven studies and 1, 779 patients, found that Cerebrolysin failed to demonstrate significant superiority on modified Rankin Scale or Barthel Index efficacy outcomes at day 90, though safety was comparable to placebo (PMID 28656143). Wang et al. (2017), pooling six RCTs and 1, 649 patients, reported that Cerebrolysin had no significant effect on functional recovery at day 90 as measured by mRS, NIHSS, or Barthel Index response, and did not increase the risk of adverse events or mortality (PMID 28458521). A 2021 safety-focused meta-analysis by Strilciuc et al., pooling 12 RCTs and 2, 202 patients, confirmed a favorable safety profile for Cerebrolysin versus placebo across all main and subgroup analyses, with a trend toward lower serious adverse event rates at the highest dose (50 mL) (PMID 34959697).

A 2023 multicenter pilot RCT (CEREHETIS) by Khasanova and Kalinin, published in the Journal of Neurology and Psychiatry, investigated the combination of Cerebrolysin with intravenous thrombolysis (alteplase) in 341 acute stroke patients. The trial reported that Cerebrolysin co-administration significantly reduced symptomatic hemorrhagic transformation (OR 0.248; 95% CI 0.072–0.851; P=0.019) and improved early neurological deficit at day 14, but found no statistically significant difference in modified Rankin Scale score at day 90 (PMID 37682097).

Vascular Dementia: Cochrane Review and RCT Evidence

The Cochrane Review of Cerebrolysin for vascular dementia by Cui et al. (2019), covering six RCTs and 597 participants, found that courses of intravenous Cerebrolysin improved cognition and general function compared to placebo (cognitive function SMD 0.36, 95% CI 0.13–0.58; global function RR 2.69, 95% CI 1.82–3.98), but rated the evidence as very low quality (PMID 31710397). The review authors stated that “if there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful, ” and called for adequately powered, methodologically robust trials. No new studies were identified since the prior Cochrane review.

An earlier industry-supported RCT by Guekht et al. (2010), published in the Journal of Stroke and Cerebrovascular Diseases, enrolled 242 subjects with vascular dementia in a multicenter, double-blind, placebo-controlled study. The trial reported significant improvements in both ADAS-cog+ (10.6-point improvement vs. 4.4-point in placebo; P<0.0001) and CIBIC+ global function scores at week 24 (PMID 20656516). These results were positive but industry-funded, and the subject population (mild-to-moderate vascular dementia) is specific.

Alzheimer’s Disease: Meta-Analysis Evidence

A meta-analysis by Gauthier et al. (2015) in Dementia and Geriatric Cognitive Disorders pooled six randomized double-blind placebo-controlled trials of Cerebrolysin 30 mL/day in mild-to-moderate Alzheimer’s disease. The analysis found that Cerebrolysin was significantly more effective than placebo on cognitive function at 4 weeks (SMD −0.40; P=0.003) and on global clinical change at both 4 weeks (OR 3.32) and 6 months (OR 4.98), with a safety profile comparable to placebo (PMID 25832905). The authors concluded the results supported “considering Cerebrolysin as a therapeutic agent” for mild-to-moderate Alzheimer’s disease. The review’s primary limitation is that contributing trials were predominantly industry-funded.

What Is Cerebrolysin’s Evidence Tier? An Honest Assessment

Cerebrolysin presents an evidence profile that is unusual in the peptide research landscape: it has been studied in multiple RCTs and reviewed by Cochrane, a level of evidence rarely available for compounds in this category. At the same time, the evidence is consistently characterized by independent reviewers as low to very low quality, results are mixed across studies, and most positive trials are industry-funded. The following table summarizes the landscape as documented in published, peer-reviewed literature.

The critical assessment to state plainly: Cerebrolysin’s clinical trial base is real and substantial by peptide-research standards, and it is a genuinely approved pharmaceutical drug in multiple countries. However, the independent Cochrane reviews consistently find the evidence insufficient to recommend routine use for stroke or vascular dementia, the quality of the available evidence is rated as very low to moderate, and many of the positive trials are industry-funded. Researchers and clinicians in jurisdictions where it is not approved should treat this evidence base as documenting a contested, debated area of clinical research, not a settled one. This publication does not take a position on the clinical merits of Cerebrolysin; it documents what the published record shows.

What Is Cerebrolysin’s Regulatory Status?

FDA (United States)

Cerebrolysin is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no FDA-approved indication, no authorized human dosing protocol, and is not legally available as a pharmaceutical in the United States. The preparation’s porcine brain tissue origin and undefined peptide fraction composition present additional regulatory considerations under FDA frameworks for biological preparations.

Approved Jurisdictions

Cerebrolysin is an approved pharmaceutical drug in Austria, where it is manufactured by EVER Neuro Pharma GmbH. It is also approved and in clinical use in Russia, China, and numerous countries across Eastern Europe and Asia. In these jurisdictions, it is prescribed and administered by licensed physicians for neurological indications including acute ischemic stroke and dementia. Approval standards, approved indications, and administration protocols vary by country; this article documents these as regulatory facts only and does not endorse use outside authorized clinical settings in jurisdictions where it is approved.

EU and Western Jurisdictions

Cerebrolysin does not hold European Medicines Agency (EMA) approval and is not registered as a medicinal product in the European Union as a whole, despite its Austrian manufacturer. It is approved at the national level in some EU member states; researchers should consult the relevant national authority for current status.

How Does Cerebrolysin Fit in the Cognitive & Neuro Cluster?

Within the Cognitive & Neuro research overview, Cerebrolysin occupies a distinct position from synthetic neuropeptide analogs such as Semax (a synthetic ACTH fragment) or Dihexa (a synthetic angiotensin IV analog). The key distinctions are: (1) Cerebrolysin is a natural-extract preparation from porcine brain tissue, not a synthetic sequence; (2) it carries an approved-drug history with a substantial RCT base; and (3) its mechanism involves the combined activity of multiple known neurotrophic factors rather than a defined single-receptor interaction. Researchers interested in comparing evidence quality across this cluster should review the Evidence Tier Methodology documentation in the guide.

Frequently Asked Questions About Cerebrolysin

What is Cerebrolysin?

Cerebrolysin is a low-molecular-weight peptide and amino acid preparation derived from porcine (pig) brain tissue. It contains neurotrophic factors including BDNF, GDNF, NGF, and CNTF alongside additional peptide fragments and free amino acids. It is an approved pharmaceutical drug in Austria, Russia, China, and numerous other countries, and has been studied in multiple randomized controlled trials for acute ischemic stroke, vascular dementia, and Alzheimer’s disease. It is not approved by the U.S. FDA.

Is Cerebrolysin FDA approved?

No. Cerebrolysin is not approved by the U.S. Food and Drug Administration for any therapeutic use. It is an approved pharmaceutical drug in Austria (where it is manufactured), Russia, China, and various Eastern European and Asian countries. These approvals reflect those countries’ regulatory standards and do not constitute FDA approval. In the United States, Cerebrolysin has no approved indication and is not legally available as a pharmaceutical.

What does the Cochrane review say about Cerebrolysin for stroke?

The Cochrane Review on Cerebrolysin for acute ischaemic stroke (Ziganshina et al., 2017; PMID 28430363), covering six RCTs and 1, 501 participants, concluded that the evidence does not demonstrate clinical benefits of Cerebrolysin for treating acute ischaemic stroke. It found moderate-quality evidence of an increase in non-fatal serious adverse events with Cerebrolysin. The review noted that three of six included studies were funded by the manufacturer. For vascular dementia, a separate Cochrane review (Cui et al., 2019) found modest positive signals but rated the evidence as very low quality and concluded it was insufficient to recommend routine use.

What is Cerebrolysin’s evidence tier in the Legendary Labz framework?

Cerebrolysin has a uniquely large body of human clinical trial data relative to most compounds in the guide, multiple RCTs and Cochrane meta-analyses, making it evidence-rich but evidence-contested. Its evidence tier reflects both the volume of clinical data and the quality limitations documented by Cochrane reviewers: inconsistent results, very low to moderate evidence quality ratings, and a concentration of positive findings in industry-funded studies. Full evidence-tier methodology is documented in the guide.

Research use only. Not intended for human use. Cerebrolysin is an approved pharmaceutical drug in Austria, Russia, China, and certain other countries; it is not approved by the U.S. Food and Drug Administration or the European Medicines Agency for any indication. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.